Cited 29 times in
Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신성재 | - |
dc.date.accessioned | 2018-07-20T08:08:53Z | - |
dc.date.available | 2018-07-20T08:08:53Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160883 | - |
dc.description.abstract | Macrolide antibiotics are cornerstones in the treatment of Mycobacterium massiliense lung disease. Despite the emergence of resistance, limited data on macrolide-resistant M massiliense lung disease are available. This study evaluated the clinical features and treatment outcomes of patients and the molecular characteristics of macrolide-resistant M massiliense isolates. We performed a retrospective review of medical records and genetic analyses of clinical isolates from 15 patients who had macrolide-resistant M massiliense lung disease between September 2005 and February 2015. Nine patients (60%) had the nodular bronchiectatic form of the disease, and six (40%) had the fibrocavitary form. Before the detection of macrolide resistance, three patients (20%) were treated with macrolide monotherapy, four (27%) with therapy for presumed Mycobacterium avium complex infections, and eight (53%) with combination antibiotic therapy for M massiliense lung disease. The median treatment duration after the detection of resistance was 18.7 months (interquartile range, 11.2 to 39.8 months). Treatment outcomes were poor, with a favorable outcome being achieved for only one patient (7%), who underwent surgery in addition to antibiotic therapy. The 1-, 3-, and 5-year mortality rates were 7, 13, and 33%, respectively. Of the 15 clinical isolates, 14 (93%) had point mutations at position 2058 (n = 9) or 2059 (n = 5) of the 23S rRNA gene, resulting in macrolide resistance. Our study indicates that treatment outcomes are poor and mortality rates are high after the development of macrolide resistance in patients with M massiliense lung disease. Thus, preventing the development of macrolide resistance should be a key consideration during treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | American Society for Microbiology | - |
dc.relation.isPartOf | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anti-Bacterial Agents/pharmacology* | - |
dc.subject.MESH | Anti-Bacterial Agents/therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Diseases/microbiology* | - |
dc.subject.MESH | Macrolides/pharmacology* | - |
dc.subject.MESH | Macrolides/therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycobacterium/drug effects* | - |
dc.subject.MESH | Mycobacterium/pathogenicity | - |
dc.subject.MESH | Mycobacterium Infections/drug therapy | - |
dc.subject.MESH | Mycobacterium Infections/microbiology | - |
dc.subject.MESH | Mycobacterium avium Complex/drug effects | - |
dc.subject.MESH | Mycobacterium avium Complex/pathogenicity | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Microbiology | - |
dc.contributor.googleauthor | Hayoung Choi | - |
dc.contributor.googleauthor | Su-Young Kim | - |
dc.contributor.googleauthor | Hyun Lee | - |
dc.contributor.googleauthor | Byung Woo Jhun | - |
dc.contributor.googleauthor | Hye Yun Park | - |
dc.contributor.googleauthor | Kyeongman Jeon | - |
dc.contributor.googleauthor | Dae Hun Kim | - |
dc.contributor.googleauthor | Hee Jae Huh | - |
dc.contributor.googleauthor | Chang-Seok Ki | - |
dc.contributor.googleauthor | Nam Yong Lee | - |
dc.contributor.googleauthor | Seung-Heon Lee | - |
dc.contributor.googleauthor | Sung Jae Shin | - |
dc.contributor.googleauthor | Charles L. Daley | - |
dc.contributor.googleauthor | Won-Jung Koh | - |
dc.identifier.doi | 10.1128/AAC.02189-16 | - |
dc.contributor.localId | A02114 | - |
dc.relation.journalcode | J00189 | - |
dc.identifier.eissn | 1098-6596 | - |
dc.identifier.pmid | 27872066 | - |
dc.contributor.alternativeName | Shin, Sung Jae | - |
dc.contributor.affiliatedAuthor | Shin, Sung Jae | - |
dc.citation.volume | 61 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | e02189-16 | - |
dc.identifier.bibliographicCitation | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Vol.61(2) : e02189-16, 2017 | - |
dc.identifier.rimsid | 60765 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.